Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine
Journal of Clinical Medicine · 08.08.2024 · 13 (16) · 4661
DOI: 10.3390/jcm13164661 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.08.2024. Verfasst von Anastasia Bougea und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Neurology, National and Kapodistrian University of Athens, 15772 Athens, Greece. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
(1)
Background
Alzheimer’s disease (AD) is a worldwide neurodegenerative disorder characterized by the buildup of abnormal proteins in the central nervous system and cognitive decline. Since no radical therapy exists, only symptomatic treatments alleviate symptoms temporarily. In this review, we will explore the latest advancements in precision medicine and biomarkers for AD, including their potential to revolutionize the way we diagnose and treat this devastating condition. (2)
Methods
A literature search was performed combining the following Medical Subject Heading (MeSH) terms on PubMed: “Alzheimer’s disease”, “biomarkers”, “APOE”, “APP”, “GWAS”, “cerebrospinal fluid”, “polygenic risk score”, “Aβ42”, “τP-181”, “ p-tau217”, “ptau231”, “proteomics”, “total tau protein”, and “precision medicine” using Boolean operators. (3)
Results
Genome-wide association studies (GWAS) have identified numerous genetic variants associated with AD risk, while a transcriptomic analysis has revealed dysregulated gene expression patterns in the brains of individuals with AD. The proteomic and metabolomic profiling of biological fluids, such as blood, urine, and CSF, and neuroimaging biomarkers have also yielded potential biomarkers of AD that could be used for the early diagnosis and monitoring of disease progression. (4)
Conclusion
By leveraging a combination of the above biomarkers, novel ultrasensitive immunoassays, mass spectrometry methods, and metabolomics, researchers are making significant strides towards personalized healthcare for individuals with AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1st Department of Neurology, National and Kapodistrian University of Athens, 15772 Athens, Greece.
- 1st Department of Psychiatry, University of Patras, 26504 Rio, Greece.
ORCID-Profile: Anastasia Bougea, Philippos Gourzis
Zitieren
APA
Bougea, A., & Gourzis, P. (2024). Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine. Journal of Clinical Medicine, 13(16), 4661. https://doi.org/10.3390/jcm13164661
Vancouver
Bougea A, Gourzis P. Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine. Journal of Clinical Medicine. 2024;13(16):4661. doi:10.3390/jcm13164661
BibTeX
@article{Bougea2024,
author = {Bougea, Anastasia and Gourzis, Philippos},
title = {Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {16},
pages = {4661},
doi = {10.3390/jcm13164661}
}
EUVIMED